TMO Q1 Earnings Call: Navigating Tariffs and Macro Uncertainty While Investing in Innovation
Life sciences company Thermo Fisher (NYSE:TMO) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales were flat year on year at $10.36 billion. Its non-GAAP profit of $5.15 per share was 0.9% above analysts’ consensus estimates. The stock remained flat at $433.50 following the earnings release and call.
Revenue: $10.36 billion vs analyst estimates of $10.23 billion (flat year on year, 1.3% beat)
Adjusted EPS: $5.15 vs analyst estimates of $5.10 (0.9% beat)
Adjusted EBITDA: $2.55 billion vs analyst estimates of $2.55 billion (24.6% margin, in line)
Operating Margin: 16.6%, in line with the same quarter last year
Free Cash Flow Margin: 3.5%, down from 8.7% in the same quarter last year
Organic Revenue rose 1% year on year (-4% in the same quarter last year)
Market Capitalization: $164.1 billion
Thermo Fisher’s first quarter results reflected stable demand across key segments, with performance led by its bioproduction, pharma services, and electron microscopy businesses. Management attributed the quarter’s outcome to strong operational execution and highlighted the impact of fewer pandemic-related sales and macroeconomic headwinds in U.S. and China academic markets. CEO Marc Casper pointed to recent product launches, such as the Vulcan automated lab and next-generation chromatography platforms, as evidence of the company’s continued investment in innovation despite external pressures.
Looking forward, management’s updated guidance incorporates challenges from new tariffs and evolving U.S. policy, especially regarding trade with China and government research funding. Casper stated, “We’re acting with speed and agility to navigate the current environment,” and emphasized ongoing mitigation strategies, including supply chain adjustments and targeted price actions. CFO Stephen Williamson noted that while these macro changes introduce uncertainty, Thermo Fisher aims to offset much of the impact through operational flexibility and investment in U.S. manufacturing and R&D.
Management’s remarks centered on the company’s ability to maintain operational performance amid a volatile external environment. Key themes included innovation, targeted investments, and navigating policy shifts.
Bioproduction and Pharma Services Momentum: Growth in the pharma and biotech segment was driven by bioproduction and pharma services, with management noting that fill-finish and tableting services for pharmaceutical customers are in high demand due to increased interest in U.S.-based manufacturing.
Academic and Government Softness: Revenue from academic and government customers declined due to reduced government funding and macro uncertainty in the U.S. and China. Management said this softness would likely continue for the remainder of the year, with recovery depending on future government appropriations.
Innovation Pipeline Launches: Several new products debuted, such as the Vulcan automated lab (an AI-enabled robotics and electron microscopy platform for semiconductor customers) and Olink Reveal proteomics kits, supporting Thermo Fisher’s positioning in precision medicine and high-throughput workflows.
M&A Activity and Strategic Investments: The pending $4.1 billion acquisition of Soventum’s purification and filtration business is expected to broaden Thermo Fisher’s bioproduction capabilities. The company also committed to investing $2 billion over four years in U.S. manufacturing and R&D, reinforcing its domestic footprint.
Tariff and Policy Mitigation: Management highlighted a proactive approach to recent U.S.-China tariffs and policy changes, estimating a $400 million revenue headwind for the year but expecting to fully offset these effects in the following year through supply chain adjustments and selective pricing actions.
Management expects the next few quarters to be shaped by tariff-related headwinds, policy-driven volatility, and ongoing investments in innovation and manufacturing. The broader theme is adaptability amid policy and macroeconomic shifts.
Tariff Mitigation and Supply Chain Flexibility: Continued adaptation to U.S.-China and other international tariffs is expected, with management emphasizing rapid supply chain adjustments and leveraging Thermo Fisher’s global manufacturing footprint to minimize disruptions.
Academic and Clinical Research Demand: Ongoing softness in U.S. academic and government spending, as well as reduced vaccine-related clinical trial activity, could constrain growth. Recovery will likely depend on future funding decisions and policy clarity.
Pricing and Innovation Investments: Management intends to deploy selective price increases (up to 2%) to offset inflation and tariff costs, while sustaining high R&D outlays and launching new products to maintain competitive advantages and support long-term growth.
Michael Ryskin (Bank of America): Asked about the rationale for a wider guidance range and how Thermo Fisher would respond to further changes in tariffs or policy. CEO Marc Casper explained that the guidance reflects agility amid evolving scenarios, with mitigation measures ready for both upsides and downsides.
Matt Sykes (Goldman Sachs): Sought clarity on customer order patterns in light of new tariffs and the company’s manufacturing flexibility. Casper replied that no material order pull-forward occurred and highlighted Thermo Fisher’s scale and geographic diversity as key to rapid supply chain adjustments.
Jack Meehan (Nephron Research): Queried about the impact of potential pharmaceutical tariffs and opportunities in U.S. reshoring. Casper described growing demand for U.S.-based manufacturing and noted that planned investments in domestic capacity are designed to capture this trend.
Rachel Vatnsdal (JPMorgan): Asked for details on the split between academic/government and clinical research headwinds in guidance, along with expectations for pricing actions. Casper estimated $200 million of lost clinical research revenue from vaccine trial cancellations and stated that price increases would be moderate and portfolio-wide.
Doug Schenkel (Wolfe Research): Questioned management on the risk of structurally lower growth rates for life sciences tools, and how Thermo Fisher would adapt. Casper acknowledged the potential for slower market growth if GDP weakens but believes the company’s scale, transparency, and diversified customer base provide resilience.
In the quarters ahead, our analysts will monitor (1) the pace and effectiveness of Thermo Fisher’s tariff mitigation actions and supply chain realignment, (2) progress on the Soventum acquisition and integration, and (3) stabilization or improvement in U.S. academic/government and clinical research demand. The pipeline of new product launches and execution on planned manufacturing and R&D investments will also be critical indicators of the company’s ability to offset ongoing external pressures.
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.
Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today.
